Stop Counting Leads: How Your CRM Architecture is Sabotaging Your ABM
By Christina Mastrocola
In the world of consulting, there really is never a dull moment. But it’s in those head-scratching moments that innovation can really happen. I recently sat down with a client, a new VP at a major B2B healthcare vendor, who asked a question that got my team buzzing.
He had looked at the dashboards, pointed to the marketing spend, and asked, “Is email actually working for us? Or is this just a legacy expense we keep justifying? Should we just kill the channel?”
In most digital marketing circles, a question like that normally would be heresy. But looking at his specific data, he was right to ask.
As we dug into the operations, we found the truth. The problem wasn’t the channel. The core issue was the architecture.
The Healthcare Reality Gap
In B2B healthcare, the game really isn’t about discovery; it’s about access. We know who the major health systems are. We know the Total Addressable Market – there are only so many hospitals out there!
The challenge is navigating the 6-10 decision-makers, clinicians, IT directors, procurement officers, and administrators with vague titles who each hold varying degrees of influence over a deal.
The reason so many healthcare organizations are failing to see ROI from their marketing spend isn’t that they just aren’t suited to email. It’s that they are running complex account-based plays and robust relationships, on a CRM built for linear, transactional sales.
If you feel like your marketing is hitting a wall, check your organization for these six symptoms:
- Stagnant Systems: Your CRM acts as a storage locker for names rather than an engine for relationships
- Lacking Data Utility: You have millions of records but cannot nurture key decision makers through the customer journey in a way that alights with Sales’s expectations
- One-Size-Fits-None Outreach: You send generic blasts just to get a message out there
- Ignoring Intent: You wait for form fills instead of acting on behavioral signals
- KPI Misalignment: Marketing celebrates volume but sales complains about “junk”
- Poor Deliverability: Your domain reputation is tanking, your emails are ending up in recipients spam and unsubscribes are keeping you up at night and you don’t really know why
The Digital Rolodex Problem
The root cause of these symptoms usually lies in the complex data model that has developed in tandem with most companies.
Most CRMs, in particular Salesforce, are still architected around the “Lead” object, a single individual. Purchasing decisions are not made by individuals, they are made by committees. Traditional lead scoring models are too limited to sift through the noise, and intent platforms are unable to truly identify readiness since Leads are innately disconnected from Accounts.
To move from “counting leads” to “influencing decisions”, stop obsessing over volume and start obsessing over Data Utility.
The Fix: Architecture First, Tactics Second
Before you buy another enrichment tool or launch another campaign, you need to prioritize fixing the overall foundation. In our recent webinar, my colleague Beau Gardner and I broke down the three steps to fixing this broken engine:
- Move from Volume to Utility: A database of 5,000 highly accurate, segmented, engaged contacts is infinitely more valuable than a database of 50,000 unverified leads. If you cannot trust the data, you cannot personalize the journey.
- Establish a strong Data Hierarchy: Can you confidently identify if a local campus is part of a larger Health System? If not, you are flying blind. Mapping relationships is essential to enable reps with the full picture of the buying committee and relationship.
- Shift from “Upselling” to “Expansion”: In modern Rev Ops, expansion is about using trust to build connections and influence the next decision maker in the network. Use intent signals to see where the clinical side is engaged, even if the administrative arm of the buying committee hasn’t bought in yet.
Ready for the full diagnosis?
Watch the full on-demand webinar “Stop Counting Leads, Start Influencing Decisions” where Beau and I dive into the specific architectural changes you need to make in your CRM to unlock true ABM in healthcare.
Closing the Trust Gap Between Marketing and Sales
Once your data model and signals reflect buying reality, you can start to repair the relationship between marketing and sales:
- Create shared definitions of “qualified.” Move away from MQL as a volume goal and towards marketing-identified qualified accounts or buying groups with clear, mutually agreed upon criteria.
- Implement feedback loops. Give sales structured ways to accept, reject and annotate opportunities at the account level, so marketing can refine models based on real outcomes rather than assumptions.
- Measure what matters to the business. Shift executive reporting from stagnant lead gen numbers to pipeline and revenue influenced within targeted systems and segments
This is the work of revenue operations. It is not glamorous, but it is what separates healthcare vendors who struggle to prove marketing’s value from those who create a reliable, scalable, account-based growth engine.
A Chronic Illness with a Cure
If you recognize your own organization in some way, shape or form in this article, you are certainly not alone.
You might be producing content and webinars, yet Sales still asks, “Give us something we can use!” You may have invested in pricey enrichment packages, yet you still rely on the heroics of a few field reps to close deals.
The good news is that these illnesses are curable, but can be chronic or lifelong if left untreated. They are not solved by “more leads.” They are solved by aligning your data, systems and teams around the accounts and buying groups that already define how healthcare already buys.
Account-based is not a buzzword for your world. It is a reflection of the reality your sales team lives in every day. When your marketing and Rev Ops infrastructure finally reflects that reality, the trust gap begins to close, conversion rates rise, and your marketing investments start to show up clearly in revenue.
